Effect of Daily Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) on Proteinuria in Pediatric Patients With Idiopathic Nephrotic Syndrome

Key facts

Sponsor

Northwell Health

Principal Investigator

Christine Sethna, MD

Northwell Health

Intervention

Transcutaneous Auricular Vagus Nerve (taVNS) stimulation(device)

Enrollment

7 target

Eligibility

2-21 years · All sexes

Timeline

2019 – 2021

Study locations (1)

• Northwell, New Hyde Park, New York, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Idiopathic nephrotic syndrome

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT06820866
  Non-invasive Diagnosis of Idiopathic Nephrotic Syndromes
  Assistance Publique - Hôpitaux de Paris
• ACTIVE NOT RECRUITINGPHASE3NCT05627557
  A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome
  Hoffmann-La Roche
• RECRUITINGNCT04207580
  A National Prospective Cohort of Patients With Idiopathic Nephrotic Syndrome Beginning in Childhood.
  University Hospital, Limoges

See all trials for Idiopathic nephrotic syndrome →